- Delivery Method:
- Via Email
Recipient NameDr. Steven A. Levin
Recipient TitleCEO and Owner
- Algunas Inc., dba Woodland Hills Compounding Pharmacy
20631 Ventura Blvd.
Woodland Hills, CA 91364
- Issuing Office:
- Division of Pharmaceutical Quality Operations IV
Dear Dr. Levin:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL# 532739) dated July 17, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
CDR Steven E Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV